MEP43808A - Polymer conjugates of mutated neublastin - Google Patents

Polymer conjugates of mutated neublastin

Info

Publication number
MEP43808A
MEP43808A MEP-438/08A MEP43808A MEP43808A ME P43808 A MEP43808 A ME P43808A ME P43808 A MEP43808 A ME P43808A ME P43808 A MEP43808 A ME P43808A
Authority
ME
Montenegro
Prior art keywords
polymer conjugates
mutated neublastin
neublastin
polymer
prolonged
Prior art date
Application number
MEP-438/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Dinah Wen-Yee Sah
R Blake Pepinsky
Paula Ann Boriack-Sjodin
Stephan S Miller
Anthony Rossomando
Laura Silvian
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/356,264 external-priority patent/US7442370B2/en
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of MEP43808A publication Critical patent/MEP43808A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
MEP-438/08A 2003-01-31 2004-02-02 Polymer conjugates of mutated neublastin MEP43808A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/356,264 US7442370B2 (en) 2001-02-01 2003-01-31 Polymer conjugates of mutated neublastin
PCT/US2004/002763 WO2004069176A2 (fr) 2001-02-01 2004-02-02 Conjugues polymeres de neublastine mutee
YU20050585A RS52910B (en) 2003-01-31 2004-02-02 POLYMER CONJUGATES OF MUTATED NEUBLASTINE

Publications (1)

Publication Number Publication Date
MEP43808A true MEP43808A (en) 2011-02-10

Family

ID=35006489

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-438/08A MEP43808A (en) 2003-01-31 2004-02-02 Polymer conjugates of mutated neublastin

Country Status (27)

Country Link
EP (3) EP2301960A3 (fr)
JP (3) JP4742025B2 (fr)
KR (2) KR101293805B1 (fr)
CN (2) CN101166753A (fr)
AT (1) ATE478891T1 (fr)
AU (1) AU2004209966B9 (fr)
BR (1) BRPI0407170A (fr)
CA (1) CA2514510C (fr)
CY (2) CY1111196T1 (fr)
DE (1) DE602004028801D1 (fr)
DK (2) DK2246362T3 (fr)
EA (1) EA008743B1 (fr)
ES (2) ES2450115T3 (fr)
GE (3) GEP20135982B (fr)
HK (1) HK1085663A1 (fr)
IL (2) IL169945A (fr)
IS (1) IS7938A (fr)
ME (1) MEP43808A (fr)
MX (1) MXPA05008168A (fr)
NO (1) NO20054025L (fr)
NZ (2) NZ581460A (fr)
PL (1) PL383683A1 (fr)
PT (2) PT1594436E (fr)
RS (1) RS52910B (fr)
SI (2) SI1594436T1 (fr)
UA (2) UA91178C2 (fr)
ZA (1) ZA200505707B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA91178C2 (ru) * 2003-01-31 2010-07-12 Байоджен Айдек Ма Інк. Мутантный неубластин
WO2006023782A2 (fr) * 2004-08-19 2006-03-02 Biogen Ideca Ma Inc. Repliement des proteines de la famille du facteur de croissance transformant beta
US20140092376A1 (en) * 2012-10-01 2014-04-03 Momentive Performance Materials, Inc. Container and method for in-line analysis of protein compositions
AU2018212403A1 (en) * 2017-01-25 2019-08-22 Tessa Therapeutics Ltd. TGF-ß decoy receptor
EP4096920A1 (fr) * 2020-01-27 2022-12-07 Silcotek Corp. Procédé et produit de fabrication biopharmaceutique

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU187037B (en) 1983-04-19 1985-10-28 Tibor Sinko Rope-stretching device
EP0154316B1 (fr) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA2006596C (fr) 1988-12-22 2000-09-05 Rika Ishikawa G-csf modifie chimiquement
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
KR100238712B1 (ko) 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
CA2092271C (fr) 1993-03-09 2009-10-13 Eddie Reed Utilisation de fsc-g pour traiter les effets secondaires du taxol
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
CA2253871C (fr) 1996-05-08 2005-04-26 Biogen, Inc. Ligand ret (retl) pour stimuler la croissance renale et neuronale
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
AU2354600A (en) * 1998-12-09 2000-06-26 Amgen, Inc. Grnf4 a neurotrophic factor
IL156559A0 (en) * 2000-12-22 2004-01-04 Genentech Inc New use of artemin, a member of the gdnf ligand family
GEP20063916B (en) * 2001-02-01 2006-09-11 Biogen Idec Inc Polymer conjugates of neublastin and methods of using same
NZ529126A (en) * 2001-03-28 2010-07-30 Biogen Idec Inc Use of neublastin polypeptides for treating allodynia, hyperalgesic pain and phantom pain
UA91178C2 (ru) * 2003-01-31 2010-07-12 Байоджен Айдек Ма Інк. Мутантный неубластин
EP1897552B1 (fr) * 2003-04-18 2009-06-17 Biogen Idec MA Inc. Conjugués polymères de neublastine et leurs procédés d'utilisation

Also Published As

Publication number Publication date
RS52910B (en) 2014-02-28
EA008743B1 (ru) 2007-08-31
DK1594436T3 (da) 2010-12-13
AU2004209966A2 (en) 2004-08-19
EA200501212A3 (ru) 2006-10-27
AU2004209966B2 (en) 2008-04-17
DE602004028801D1 (de) 2010-10-07
ES2450115T3 (es) 2014-03-24
ES2351215T3 (es) 2011-02-01
KR101216331B1 (ko) 2012-12-28
CN102367277A (zh) 2012-03-07
GEP20115137B (en) 2011-01-10
PT2246362E (pt) 2014-03-10
UA91178C2 (ru) 2010-07-12
ATE478891T1 (de) 2010-09-15
EP1594436B1 (fr) 2010-08-25
EP2246362A2 (fr) 2010-11-03
CN102367277B (zh) 2014-04-09
IS7938A (is) 2005-07-12
EP2301960A3 (fr) 2011-08-03
DK2246362T3 (en) 2014-03-10
EP2246362B1 (fr) 2013-12-18
CY1115085T1 (el) 2016-12-14
JP2010184924A (ja) 2010-08-26
GEP20084464B (en) 2008-08-25
KR101293805B1 (ko) 2013-08-06
UA105892C2 (uk) 2014-07-10
SI1594436T1 (sl) 2011-01-31
RS20050585A (en) 2007-11-15
CA2514510C (fr) 2013-10-01
CA2514510A1 (fr) 2004-08-19
EA200501212A2 (ru) 2006-08-25
JP4742025B2 (ja) 2011-08-10
KR20050099514A (ko) 2005-10-13
GEP20135982B (en) 2013-12-10
PL383683A1 (pl) 2008-04-14
NZ541921A (en) 2010-01-29
AU2004209966B9 (en) 2008-06-26
SI2246362T1 (sl) 2014-04-30
IL169945A (en) 2015-03-31
CN101166753A (zh) 2008-04-23
JP2007525152A (ja) 2007-09-06
EP1594436A2 (fr) 2005-11-16
EP2246362A3 (fr) 2011-02-23
MXPA05008168A (es) 2005-10-05
NZ581460A (en) 2010-02-26
PT1594436E (pt) 2010-11-29
CY1111196T1 (el) 2015-06-11
BRPI0407170A (pt) 2006-02-21
AU2004209966A1 (en) 2004-08-19
NO20054025D0 (no) 2005-08-30
HK1085663A1 (en) 2006-09-01
NO20054025L (no) 2005-10-31
EP2301960A2 (fr) 2011-03-30
IL227752A0 (en) 2013-09-30
EP1594436A4 (fr) 2008-05-28
ZA200505707B (en) 2007-01-31
KR20120099161A (ko) 2012-09-06
JP2011078434A (ja) 2011-04-21

Similar Documents

Publication Publication Date Title
MY151184A (en) A polypeptide complex comprising non-peptidyl polymer having three functional ends
CY1106789T1 (el) Γενικος φορεας για στοχευση μοριων σε κυτταρα που εκφραζουν gb3 υποδοχεα
DE60333776D1 (de) Pharmazeutische und kosmetische zubereitungen
PL369741A1 (en) Immunocytokines with modulated selectivity
MEP43808A (en) Polymer conjugates of mutated neublastin
DK1860187T3 (da) Apo-2-receptor
CY1116055T1 (el) Σκευασματα υδροξυματαιρεσινολης για τοπικη εφαρμογη
FR2632519B1 (fr) Composition parfumante, a phase aqueuse continue, ayant une forte concentration en parfum
ATE433759T1 (de) Polymerkonjugiertes glycosiliertes neublastin
BR0108056A (pt) Preparados cosméticos com extratos waltheria indica
ME00483B (me) Parenteralni sastav paracetamola
Glocker et al. Selective biochemical modification of functional residues in recombinant human macrophage colony-stimulating factor β (rhM-CSF β): identification by mass spectrometry
IS5998A (is) Notkun mótefna til bólusetningar gegn krabbameini
DE60317565D1 (de) Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden
EA200401331A1 (ru) Фармацевтическая препаративная форма, включающая мелатонин
ATE223701T1 (de) Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
ATE344223T1 (de) Vitamin d-analoge
NO20044901L (no) Anvendelse av modifiserte novirhabdoviruser i vaksiner
DE60112476D1 (de) Glucuronyl-c5-epimerase der maus, diese codierende dna und deren verwendung
BR0113579A (pt) Proteìnas sintéticas modificadas por polìmero
BR8101417U (pt) Banquinho portátil
DE60315069D1 (de) Alkylsulfanylbenzole als duftstoffe
ES2167276B1 (es) Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
TR200301731U (tr) Mobilya
DE60212474D1 (de) Verwendung von Alkyl 3-(N-alkylacetamino)propionat Derivaten als Feuchthaltemittel